The gut microbiome exerts profound influence on immunological and metabolic health.
Recent research points to two “next generation” microbes– Akkermansia muciniphila and Faecalibacterium prausnitzii –as especially important metabolically and immunologically. In healthy people, these organisms are plentiful. But they are found at much lower levels in people with obesity and other metabolic and inflammatory diseases.
There’s a strong clinical rationale for increasing the levels of Akkermansia and Faecalibacterium. But these next generation microbes do not tolerate oxygen well, and are not available as probiotics (exogenously administered, live microbes with strain-specific, disease-specific clinical benefits).
Until now, there were few options for augmenting these important organisms.
But a new study shows that a probiotic strain called Bifidobacterium lactis B420—itself metabolically active—can raise levels of Akkermansia in individuals with overweight or obesity. Further, an eight-strain probiotic combination was found to raise levels of both A. mucinophila and F. prausnitzii.
In this free webinar, Noelle Patno, PhD, explores the role of Akkermansia and Faecalibacterium in human metabolic and immunologic health, and review the emerging science on application of probiotics like B. lactis B420 to augment the levels of these vital “next generation” microbes.
- Review microbiome associations with immune and metabolic health
- Identify endogenous next-generation microbes as biomarkers of health
- Explain the clinical trial on B. lactis B420 related to obesity and Akkermansia
- Cover published evidence on eight probiotic strains, their mechanisms,and clinical data
- Describe a pilot study on an eight-strain probiotic combination
This webinar is co-sponsored by HOWARU® probiotics and the Metagenics Institute.
Noelle Patno, PhD, holds a doctorate in Molecular Metabolism and Nutrition from the University of Chicago. She began her career as an engineer at Abbott Laboratories after graduating as a chemical engineer from Stanford University with honors and with distinction. Her prior experience in the pharmaceutical and medical device world spanned research & development, supply chain and project management, and international technology transfer. Her current role as Therapeutic Platform Lead at Metagenics includes researching new ingredients, primarily probiotics and prebiotics, designing clinical trials, and developing educational content on digestive and immune health.
HOWARU® premium probiotic strains power probiotic brands that are focused on efficacy and quality. With more than 100 years of probiotic development and manufacturing experience, our scientists have studied thousands of strains, and selected strains with clinically demonstrated benefits to be designated as HOWARU®.
HOWARU® Single strains and pre-formulated blends have been studied under Good Clinical Practice guidelines to ensure the highest scientific and ethical standards and appear in leading peer-reviewed publications and evidence-based guidelines. When you recommend probiotics check to see if the brand you are recommending contains HOWARU® probiotic strains. Feel free to check out the website https://www.howaru.com/hcp/ to learn more about HOWARU® strain clinical data and commitment to quality. Check in periodically to review the latest scientific information on probiotics from the world leading manufacturers of probiotic strains.